Social and family load of Alzheimer’s disease

Applied Economics

Volumn 48, Issue 21, 2016, Pages 1936-1948

  Maresova, Petra ^a   Mohelska, Hana ^a   Kuca, Kamil ^a,b  

^a UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Alzheimer s disease; costs; dementia; early diagnosis; social aspect

Indexed keywords

COMPARATIVE STUDY; MENTAL HEALTH; NERVOUS SYSTEM DISORDER; WORLD HEALTH ORGANIZATION;

EID: 84958935729     PISSN: 00036846     EISSN: 14664283     Source Type: Journal    
DOI: 10.1080/00036846.2015.1111986     Document Type: Article

References (58)

1. R.F.Allegri,, R.L.Judith Butman, G.M.Arizaga, F.E.Cecilia Serrano, D.S.Taragano, and L.Lon. 2007. “Economic Impact of Dementia in Developing Countries: An Evaluation of Costs of Alzheimer-Type Dementia in Argentina.” International Psychogeriatrics/IPA 19 (4): 705–718. doi:10.1017/S1041610206003784.
2. ‘Alzheimer Europe: Annual Report. In: Alzheimer Europe: Dementia.’ 2011. Alzheimer’s Disease International 2011 (ADI 2011). http://www.alzheimer-europe.org/Alzheimer-Europe/Our-work/Annual-Reports/Annual-Report-2011#fragment-1.
3. A.Arai,, T.Matsumoto, M.Ikeda, and Y.Arai. 2007. “Do Family Caregivers Perceive More Difficulty When They Look after Patients with Early Onset Dementia Compared to Those with Late Onset Dementia?” International Journal of Geriatric Psychiatry 22 (12): 1255–1261. doi:10.1002/gps.1935.
4. R.L.Arizaga,, R.F.Allegri, and J.A.Ollari. 2005. “The Economic Cost of Alzheimer’s Disease: Family or Public Health Burden?” Accessed July. http://www.demneuropsy.com.br/detalhe_artigo.asp?id=238.
5. C.Bakker,, M.E.de Vugt, M.Vernooij-Dassen, D.van Vliet, F.R.J.Verhey, and R.T.C.M.Koopmans. 2010. “Needs in Early Onset Dementia: A Qualitative Case from the NeedYD Study.” American Journal of Alzheimer’s Disease and Other Dementias 25 (8): 634–640. doi:10.1177/1533317510385811.
6. S.Banerjee,, and R.Wittenberg. 2009. “Clinical and Cost Effectiveness of Services for Early Diagnosis and Intervention in Dementia.” International Journal of Geriatric Psychiatry 24 (7): 748–754. doi:10.1002/gps.2191.
7. J.H.Barnett,, L.Lewis, A.D.Blackwell, and M.Taylor. 2014. “Early Intervention in Alzheimer’s Disease: A Health Economic Study of the Effects of Diagnostic Timing.” BMC Neurology 14 (1): 101. doi:10.1186/1471-2377-14-101.
8. J.Birks, 2006. “Cholinesterase Inhibitors for Alzheimer’s Disease.” The Cochrane Database of Systematic Reviews, no. 1: CD005593. doi:10.1002/14651858.CD005593.
9. R.Brookmeyer,, M.M.Corrada, F.C.Curriero, and K.Claudia. 2005. “Survival Follwing a Diagnosis of Alzheimer Disease.” http://www.medicine.mcgill.ca/epidemiology/courses/679/2005/Brookmeyer%20Archives%202002.pdf.
10. D.M.Castro,, C.Dillon, G.Machnicki, and R.F.Allegri 2010. “The Economic Cost of Alzheimer ’S Disease: Family or Public Health Burden?” 4 (4): 262–267. http://www.demneuropsy.com.br/detalhe_artigo.asp?id=238.
11. M.C.Cavallo,, and G.Fattore. 1997. “The Economic and Social Burden of Alzheimer Disease on Families in the Lombardy Region of Italy.” Alzheimer Disease and Associated Disorders 11 (4): 184–190.
12. N.Costa,, H.Derumeaux, T.Rapp, V.Garnault, L.Ferlicoq, S.Gillette, S.Andrieu, et al. 2012. “Methodological Considerations in Cost of Illness Studies on Alzheimer Disease.” Health Economics Review 2 (1): 18. doi:10.1186/2191-1991-2-18.
13. K.E.Covinsky,, R.Newcomer, P.Fox, J.Wood, L.Sands, K.Dane, and K.Yaffe. 2003. “Patient and Caregiver Characteristics Associated with Depression in Caregivers of Patients with Dementia.” Journal of General Internal Medicine 18 (12): 1006–1014. doi:10.1111/j.1525-1497.2003.30103.x.
14. R.S.Doody,, D.S.Geldmacher, B.Gordon, C.A.Perdomo, R.D.Pratt, and D.S.Group. 2001. “Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients with Alzheimer Disease.” Archives of Neurology 58 (3): 427–433.
15. F.Ducharme, 2014. “Caring for Individuals with Early-Onset Dementia and Their Family Caregivers: The Perspective of Health Care Professionals.” Advances in Alzheimer’s Disease 3 (1): 33–43. doi:10.4236/aad.2014.31005.
16. F.Ducharme,, M.-J.Kergoat, P.Antoine, F.Pasquier, and R.Coulombe. 2013. “The Unique Experience of Spouses in Early-Onset Dementia.” American Journal of Alzheimer’s Disease and Other Dementias 28 (6): 634–641. doi:10.1177/1533317513494443.
17. H.Feldman,, S.Gauthier, J.Hecker, B.Vellas, M.Hux, Y.Xu, E.M.Schwam, S.Shah, V.Mastey, and Donepezil MSAD Study Investigators Group. 2004. “Economic Evaluation of Donepezil in Moderate to Severe Alzheimer Disease.” Neurology 63 (4): 644–650.
18. A.Freyne,, N.Kidd, R.Coen, and B.A.Lawlor. 1999. “Burden in Carers of Dementia Patients: Higher Levels in Carers of Younger Sufferers.” International Journal of Geriatric Psychiatry 14 (9): 784–788. doi:10.1002/(SICI)1099-1166(199909)14:9<784::AID-GPS16>3.0.CO;2-2.
19. J.R.Frytak,, H.J.Henk, Y.Zhao, L.Bowman, J.A.Flynn, and M.Nelson. 2008. “Health Service Utilization among Alzheimer’s Disease Patients: Evidence from Managed Care.” Alzheimer’s & Dementia 4 (5): 361–367. doi:10.1016/j.jalz.2008.02.007.
20. C.Gervès,, P.Chauvin, and M.M.Bellanger. 2014. “Evaluation of Full Costs of Care for Patients with Alzheimer’s Disease in France: The Predominant Role of Informal Care.” Health Policy 116 (1): 114–122. doi:10.1016/j.healthpol.2014.01.001.
21. D.Getsios,, K.J.Steve Blume, G.M.Ishak, and L.Hernández. 2012. “An Economic Evaluation of Early Assessment for Alzheimer’s Disease in the United Kingdom.” Alzheimer’s & Dementia 8 (1): 22–30. doi:10.1016/j.jalz.2010.07.001.
22. C.Green, 2007. “Modelling Disease Progression in Alzheimer’s Disease: A Review of Modelling Methods Used for Cost-Effectiveness Analysis.” PharmacoEconomics 25 (9): 735–750.
23. ‘Health models.’ 2014. CC BY 3.0 CZ. Wikiscripts. http://www.wikiskripta.eu/index.php/Z%C3%A1kladn%C3%AD_modely_zdravotnick%C3%BDch_syst%C3%A9m%C5%AF.
24. U.Henz, 2004. “The Effects of Informal Care on Paid-Work Participation in Great Britain: A Lifecourse Perspective.” Ageing and Society 24 (6): 851–880.
25. B.Ibach,, and E.Haen. 2004. “Acetylcholinesterase Inhibition in Alzheimer’s Disease.” Current Pharmaceutical Design 10 (3): 231–251.
26. ‘Institute for Health Metrics and Evaluation (IHME).’ 2015. http://www.healthdata.org/gbd.
27. ‘JNDP Research Strategy.’ 2014. http://www.neurodegenerationresearch.eu/.
28. V.John,, G.Robert, D.Yashodhara, and M.Guruprasaadh. 2007. “Alzheimer’s Disease and Cost-Effectiveness Analyses: Ensuring Good Value for Money?” ACT–AD Accelerate Cure/Treatments for Alzheimer’s Disease 2007 (May).
29. R.W.Jones,, R.Renee Romeo, M.Trigg, A.Knapp, D.K.Sato, T.Niecko, and L.Lacey. 2015. “Dependence in Alzheimer’s Disease and Service Use Costs, Quality of Life, and Caregiver Burden: The DADE Study.” Alzheimer’s & Dementia 11 (3): 280–290. doi:10.1016/j.jalz.2014.03.001.
30. A.T.Joyce,, Y.Zhao, L.Bowman, J.A.Flynn, C.T.Carter, and D.A.Ollendorf. 2007. “Burden of Illness among Commercially Insured Patients with Alzheimer’s Disease.” Alzheimer’s & Dementia 3 (3): 204–210. doi:10.1016/j.jalz.2007.04.373.
31. L.-B.Julio,, H.Warren, G.-P.Lidia, and L.Renata. 2009. “Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer’s Disease.” Journal of Alzheimer’s Disease, no. 2: 399–407. doi:10.3233/JAD-2009-0965.
32. S.Kaiser,, and P.K.Panegyres. 2007. “The Psychosocial Impact of Young Onset Dementia on Spouses.” American Journal of Alzheimer’s Disease and Other Dementias 21 (6): 398–402. doi:10.1177/1533317506293259.
33. J.Kašpárková, 2013. “Plans for Alzheimer’s – Need or Necessity Indulgence?” Geriatrics and Gerontology 2 (3): 154–157.
34. M.Knapp,, M.Knapp, A.Comas-Herrera, A.Somani, and S.Banerjee 2007. “Dementia: Summary Report for the National Audit Office International Comparisons.” Personal Social Services Research Unit London School of Economics and Political Science Houghton Street London WC2A 2AE. http://www.pssru.ac.uk/pdf/dp2418.pdf.
35. P.-J.Lin,, D.I.Kaufer, M.L.Maciejewski, R.Ganguly, J.E.Paul, and A.K.Biddle. 2010. “An Examination of Alzheimer’s Disease Case Definitions Using Medicare Claims and Survey Data.” Alzheimer’s & Dementia 6 (4): 334–341. doi:10.1016/j.jalz.2009.09.001.
36. S.Lockeridge,, and J.Simpson. 2013. “The Experience of Caring for a Partner with Young Onset Dementia: How Younger Carers Cope.” Dementia 12 (5): 635–651. doi:10.1177/1471301212440873.
37. P.Marešová,, H.Mohelská, J.Dolejš, and K.Kuča. 2015. “Socio-economic Aspects of Alzheimer’s Disease.” Current Alzheimer Research 12 (9): 903–911.
38. M.M.Mesulam,, and C.Geula. 1994. “Butyrylcholinesterase Reactivity Differentiates the Amyloid Plaques of Aging from Those of Dementia.” Annals of Neurology 36 (5): 722–727. doi:10.1002/ana.410360506.
39. H.Mohelska,, P.Maresova, M.Valis, and K.Kuca. 2015. “Alzheimer’s Disease and Its Treatment Costs: Case Study in the Czech Republic.” Neuropsychiatric Disease and Treatment September: 2349. doi:10.2147/NDT.S87503.
40. M.J.Moore,, C.W.Zhu, and E.C.Clipp. 2001. “Informal Costs of Dementia Care: Estimates from the National Longitudinal Caregiver Study.” The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 56 (4): S219–S228.
41. T.Muller, 2007. “Rivastigmine in the Treatment of Patients with Alzheimer´s Disease.” Neuropsychiatric Disease and Treatment 3 (2): 211–218.
42. M.Pinquart,, and S.Sörensen. 2006. “Helping Caregivers of Persons with Dementia: Which Interventions Work and How Large Are Their Effects?” International Psychogeriatrics/IPA 18 (4): 577–595. doi:10.1017/S1041610206003462.
43. M.Racchi,, M.Mazzucchelli, and E.Porrello. 2004. “Acetylcholinesterase Inhibitors: Novel Activities of Old Molecules.” Pharmacological Research 50 (4): 441–451.
44. P.Roach,, J.Keady, P.Bee, and K.Hope. 2008. “Subjective Experiences of Younger People with Dementia and Their Families: Implications for UK Research, Policy and Practice.” Reviews in Clinical Gerontology 18 (2): 165. doi:10.1017/S0959259809002779.
45. B.Schoenmakers,, J.De Lepeleire, M.Ylieff, O.Fontaine, and F.Buntinx. 2004. “The Burden of Family Care Giving in Dementia.” Archives of Public Health 2004 (62): 157–172.
46. L.Schwarzkopf,, P.Menn, S.Kunz, R.Holle, J.Lauterberg, P.Marx, and H.Mehlig, et al. 2011. “Costs of Care for Dementia Patients in Community Setting: An Analysis for Mild and Moderate Disease Stage.” Value in Health 14 (6): 827–835. doi:10.1016/j.jval.2011.04.005.
47. L.Sibener,, H.M.Ibrahim Zaganjor, L.J.Snyder, R.E.Bain, and M.C.Carrillo. 2014. “Alzheimer’s Disease Prevalence, Costs, and Prevention for Military Personnel and Veterans.” Alzheimer’s & Dementia 10 (3): S105–S110. doi:10.1016/j.jalz.2014.04.011.
48. O.Soukup,, D.Jun, J.Zdarova-Karasova, J.Patocka, K.Musilek, J.Korabecny, and J.Krusek et al. 2013. “A Resurrection of 7-MEOTA: A Comparison with Tacrine.” Current Alzheimer Research 10 (8): 893–906.
49. C.K.Spiess,, and A.Ulrike Schneider. 2003. “Interactions between Care-Giving and Paid Work Hours among European Midlife Women, 1994 to 1996.” Ageing and Society 23 (1): 41–68. doi:10.1017/S0144686X02001010.
50. D.Trepel, 2010. “An Economic Perspective of Dementia Care in Ireland: Maximising Benefits and Maintaining Cost Efficiency.” Policy Paper 1. https://www.alzheimer.ie/Alzheimer/media/SiteMedia/Summary-version-of-An-Economic-Perspective-of-Dementia-Care-in-Ireland.pdf?ext=.pdf.
51. D.L.Weimer,, and M.A.Sager. 2009. “Early Identification and Treatment of Alzheimer’s Disease: Social and Fiscal Outcomes.” Alzheimer’s & Dementia 5 (3): 215–226. doi:10.1016/j.jalz.2009.01.028.
52. ‘Wikipedia.’ 2015. List of Sovereign States Anddependent Territories in Europe. Accessed 15 October. https://en.wikipedia.org/wiki/List_of_sovereign_states_and_dependent_territories_in_Europe.
53. T.Williams, 2001. “From Pillar to Post - A Study of Younger People with Dementia.” Psychiatric Bulletin 25 (10): 384–387. doi:10.1192/pb.25.10.384.
54. B.Winblad,, L.Kilander, S.Eriksson, L.Minthon, S.Båtsman, A.-L.Wetterholm, C.Jansson-Blixt, and A.Haglund. 2006. “Donepezil in Patients with Severe Alzheimer’s Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study.” The Lancet 367 (9516): 1057–1065. doi:10.1016/S0140-6736(06)68350-5.
55. World Health Organization, and Regional Office for Europe. 2013. Health 2020: A European Policy Framework and Strategy for the 21st Century. http://public.eblib.com/choice/publicfullrecord.aspx?p=1582970.
56. S.H.Zarit,, M.A.Parris Stephens, A.Townsend, and R.Greene. 1998. “Stress Reduction for Family Caregivers: Effects of Adult Day Care Use.” 53 (B): 267–277. http://psychsocgerontology.oxfordjournals.org/content/53B/5/S267.full.pdf.
57. F.Zemek,, L.Drtinova, E.Nepovimova, V.Sepsova, J.Korabecny, J.Klimes, and K.Kuca. 2014. “Outcomes of Alzheimer’s Disease Therapy with Acetylcholinesterase Inhibitors and Memantine.” Expert Opinion on Drug Safety 13 (6): 759–774. doi:10.1517/14740338.2014.914168.
58. M.Žumárová, 2012. Subjektivní pohoda a kvalita života seniorů. Prešov: Akcent Print.